PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, is pleased to announce that the first ...

The molecule, developed by its biotech division Sathgen Therapeutics, is currently undergoing Phase 1a clinical trials.

Eleva, a pioneer in discovering and developing previously inaccessible biologics based on a breakthrough technology platform, announced today the first dosing in its Phase 1 clinical study ...

Theta Capital, the largest European investor in blockchain venture capital, has announced two senior hires. Gijs Burgers has ...